Survey of Pharmacoeconomic Assessment Activity in Eleven Countries:
Policy-makers responsible for publicly-funded drug programmes face continual pressures between the demand to accommodate a steady stream of new and more effective drugs and the ongoing requirement to control costs. In the face of these pressures, a growing number of OECD countries are applying '...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Weitere Verfasser: | , |
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Paris
OECD Publishing
2003
|
| Schriftenreihe: | OECD Health Working Papers
no.4 |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | Policy-makers responsible for publicly-funded drug programmes face continual pressures between the demand to accommodate a steady stream of new and more effective drugs and the ongoing requirement to control costs. In the face of these pressures, a growing number of OECD countries are applying 'pharmacoeconomic assessment' (health technology assessment for drugs) - to new drugs to guide decisions about accepting such products for reimbursement under their public programme, or to inform negotiations about pricing. This paper provides an analytical overview of the developing practice of pharmacoeconomic assessment in eleven OECD countries. It looks at the objectives of the activity, some of its processes and some of its impacts. It does this by drawing on a literature review and on an exploratory survey of the activities of pharmacoeconomic agencies in the eleven countries. It also reviews briefly the state of pharmacoeconomic assessment in the United States. The main conclusions are as ... |
| Beschreibung: | 1 Online-Ressource (44 p.) 21 x 29.7cm. |
| DOI: | 10.1787/678644556018 |
Internformat
MARC
| LEADER | 00000cam a22000002 4500 | ||
|---|---|---|---|
| 001 | ZDB-13-SOC-061297550 | ||
| 003 | DE-627-1 | ||
| 005 | 20231204121455.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210204s2003 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1787/678644556018 |2 doi | |
| 035 | |a (DE-627-1)061297550 | ||
| 035 | |a (DE-599)KEP061297550 | ||
| 035 | |a (FR-PaOEC)678644556018 | ||
| 035 | |a (EBP)061297550 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a I11 |2 jelc | ||
| 100 | 1 | |a Dickson, Michael |e VerfasserIn |4 aut | |
| 245 | 1 | 0 | |a Survey of Pharmacoeconomic Assessment Activity in Eleven Countries |c Michael, Dickson, Jeremy, Hurst and Stephane, Jacobzone |
| 264 | 1 | |a Paris |b OECD Publishing |c 2003 | |
| 300 | |a 1 Online-Ressource (44 p.) |c 21 x 29.7cm. | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a OECD Health Working Papers |v no.4 | |
| 520 | |a Policy-makers responsible for publicly-funded drug programmes face continual pressures between the demand to accommodate a steady stream of new and more effective drugs and the ongoing requirement to control costs. In the face of these pressures, a growing number of OECD countries are applying 'pharmacoeconomic assessment' (health technology assessment for drugs) - to new drugs to guide decisions about accepting such products for reimbursement under their public programme, or to inform negotiations about pricing. This paper provides an analytical overview of the developing practice of pharmacoeconomic assessment in eleven OECD countries. It looks at the objectives of the activity, some of its processes and some of its impacts. It does this by drawing on a literature review and on an exploratory survey of the activities of pharmacoeconomic agencies in the eleven countries. It also reviews briefly the state of pharmacoeconomic assessment in the United States. The main conclusions are as ... | ||
| 650 | 4 | |a Social Issues/Migration/Health | |
| 700 | 1 | |a Hurst, Jeremy |e MitwirkendeR |4 ctb | |
| 700 | 1 | |a Jacobzone, Stephane |e MitwirkendeR |4 ctb | |
| 856 | 4 | 0 | |l FWS01 |p ZDB-13-SOC |q FWS_PDA_SOC |u https://doi.org/10.1787/678644556018 |3 Volltext |
| 912 | |a ZDB-13-SOC | ||
| 912 | |a ZDB-13-SOC | ||
| 951 | |a BO | ||
| 912 | |a ZDB-13-SOC | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-13-SOC-061297550 |
|---|---|
| _version_ | 1804748651588747264 |
| adam_text | |
| any_adam_object | |
| author | Dickson, Michael |
| author2 | Hurst, Jeremy Jacobzone, Stephane |
| author2_role | ctb ctb |
| author2_variant | j h jh s j sj |
| author_facet | Dickson, Michael Hurst, Jeremy Jacobzone, Stephane |
| author_role | aut |
| author_sort | Dickson, Michael |
| author_variant | m d md |
| building | Verbundindex |
| bvnumber | localFWS |
| collection | ZDB-13-SOC |
| ctrlnum | (DE-627-1)061297550 (DE-599)KEP061297550 (FR-PaOEC)678644556018 (EBP)061297550 |
| discipline | Wirtschaftswissenschaften |
| doi_str_mv | 10.1787/678644556018 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02220cam a22003732 4500</leader><controlfield tag="001">ZDB-13-SOC-061297550</controlfield><controlfield tag="003">DE-627-1</controlfield><controlfield tag="005">20231204121455.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210204s2003 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1787/678644556018</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627-1)061297550</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)KEP061297550</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(FR-PaOEC)678644556018</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EBP)061297550</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">I11</subfield><subfield code="2">jelc</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Dickson, Michael</subfield><subfield code="e">VerfasserIn</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Survey of Pharmacoeconomic Assessment Activity in Eleven Countries</subfield><subfield code="c">Michael, Dickson, Jeremy, Hurst and Stephane, Jacobzone</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Paris</subfield><subfield code="b">OECD Publishing</subfield><subfield code="c">2003</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (44 p.)</subfield><subfield code="c">21 x 29.7cm.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">OECD Health Working Papers</subfield><subfield code="v">no.4</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Policy-makers responsible for publicly-funded drug programmes face continual pressures between the demand to accommodate a steady stream of new and more effective drugs and the ongoing requirement to control costs. In the face of these pressures, a growing number of OECD countries are applying 'pharmacoeconomic assessment' (health technology assessment for drugs) - to new drugs to guide decisions about accepting such products for reimbursement under their public programme, or to inform negotiations about pricing. This paper provides an analytical overview of the developing practice of pharmacoeconomic assessment in eleven OECD countries. It looks at the objectives of the activity, some of its processes and some of its impacts. It does this by drawing on a literature review and on an exploratory survey of the activities of pharmacoeconomic agencies in the eleven countries. It also reviews briefly the state of pharmacoeconomic assessment in the United States. The main conclusions are as ...</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Social Issues/Migration/Health</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hurst, Jeremy</subfield><subfield code="e">MitwirkendeR</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jacobzone, Stephane</subfield><subfield code="e">MitwirkendeR</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="q">FWS_PDA_SOC</subfield><subfield code="u">https://doi.org/10.1787/678644556018</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">BO</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| id | ZDB-13-SOC-061297550 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-16T15:07:16Z |
| institution | BVB |
| language | English |
| open_access_boolean | |
| owner | DE-863 DE-BY-FWS |
| owner_facet | DE-863 DE-BY-FWS |
| physical | 1 Online-Ressource (44 p.) 21 x 29.7cm. |
| psigel | ZDB-13-SOC |
| publishDate | 2003 |
| publishDateSearch | 2003 |
| publishDateSort | 2003 |
| publisher | OECD Publishing |
| record_format | marc |
| series2 | OECD Health Working Papers |
| spelling | Dickson, Michael VerfasserIn aut Survey of Pharmacoeconomic Assessment Activity in Eleven Countries Michael, Dickson, Jeremy, Hurst and Stephane, Jacobzone Paris OECD Publishing 2003 1 Online-Ressource (44 p.) 21 x 29.7cm. Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier OECD Health Working Papers no.4 Policy-makers responsible for publicly-funded drug programmes face continual pressures between the demand to accommodate a steady stream of new and more effective drugs and the ongoing requirement to control costs. In the face of these pressures, a growing number of OECD countries are applying 'pharmacoeconomic assessment' (health technology assessment for drugs) - to new drugs to guide decisions about accepting such products for reimbursement under their public programme, or to inform negotiations about pricing. This paper provides an analytical overview of the developing practice of pharmacoeconomic assessment in eleven OECD countries. It looks at the objectives of the activity, some of its processes and some of its impacts. It does this by drawing on a literature review and on an exploratory survey of the activities of pharmacoeconomic agencies in the eleven countries. It also reviews briefly the state of pharmacoeconomic assessment in the United States. The main conclusions are as ... Social Issues/Migration/Health Hurst, Jeremy MitwirkendeR ctb Jacobzone, Stephane MitwirkendeR ctb FWS01 ZDB-13-SOC FWS_PDA_SOC https://doi.org/10.1787/678644556018 Volltext |
| spellingShingle | Dickson, Michael Survey of Pharmacoeconomic Assessment Activity in Eleven Countries Social Issues/Migration/Health |
| title | Survey of Pharmacoeconomic Assessment Activity in Eleven Countries |
| title_auth | Survey of Pharmacoeconomic Assessment Activity in Eleven Countries |
| title_exact_search | Survey of Pharmacoeconomic Assessment Activity in Eleven Countries |
| title_full | Survey of Pharmacoeconomic Assessment Activity in Eleven Countries Michael, Dickson, Jeremy, Hurst and Stephane, Jacobzone |
| title_fullStr | Survey of Pharmacoeconomic Assessment Activity in Eleven Countries Michael, Dickson, Jeremy, Hurst and Stephane, Jacobzone |
| title_full_unstemmed | Survey of Pharmacoeconomic Assessment Activity in Eleven Countries Michael, Dickson, Jeremy, Hurst and Stephane, Jacobzone |
| title_short | Survey of Pharmacoeconomic Assessment Activity in Eleven Countries |
| title_sort | survey of pharmacoeconomic assessment activity in eleven countries |
| topic | Social Issues/Migration/Health |
| topic_facet | Social Issues/Migration/Health |
| url | https://doi.org/10.1787/678644556018 |
| work_keys_str_mv | AT dicksonmichael surveyofpharmacoeconomicassessmentactivityinelevencountries AT hurstjeremy surveyofpharmacoeconomicassessmentactivityinelevencountries AT jacobzonestephane surveyofpharmacoeconomicassessmentactivityinelevencountries |